Test Price
2,800 AED✅ Home Collection Available
FHL1 Gene Emery-Dreifuss Muscular Dystrophy Type 6 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل جين FHL1 لحثل إيمري-درايفوس العضلي من النوع السادس (NGS) في الإمارات | 2800 درهم | إرشادات هيئة الصحة بدبي 2026
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- ✓ Premium Logistics: Pain-Free Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a specialist physician.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي: يقدم هذا الفحص الجيني المتطور تسلسل جين FHL1 كاملاً بأحدث تقنيات الجيل التالي (NGS) وفق معايير الآيزو 9001:2015 ودقة تشخيصية 99.9%، مع خدمة سحب منزلي آمن وبارد عبر فريق تمريض متنقل، ودعم طبي استشاري بعد النتيجة، وكل ذلك متوافق بالكامل مع قانون المرسوم بقانون اتحادي رقم 41 لسنة 2024 (المادة 87) وقانون حماية بيانات الصحة في الإمارات.
Clinical Overview
The FHL1 gene NGS test detects pathogenic variants responsible for Emery-Dreifuss Muscular Dystrophy Type 6 (EDMD6), a rare X-linked neuromuscular disorder marked by early joint contractures, slowly progressive muscle weakness, and life-threatening cardiac conduction defects. This high-coverage next-generation sequencing provides a definitive molecular diagnosis, enabling tailored cardiac surveillance, orthopedic management, and accurate family risk assessment.
| Feature | Our Test (NGS) | Closest Alternative (Sanger / Small Panel) |
|---|---|---|
| Precision & Coverage | Full-gene analysis of FHL1 with 100% coverage of all exons, intron-exon boundaries, and deep intronic regions | Targeted sequencing limited to known hotspots; may miss novel or large deletions/duplications |
| Methodology | NGS on Illumina NovaSeq™ platform with clinically validated bioinformatics pipeline | Sanger sequencing or small capture panel; lower sensitivity for mosaicism |
| Turnaround Time | 3–4 Weeks | 4–8 Weeks (fragmented workflow) |
Physician Insight & Safety Protocol
“As a neurologist deeply involved in neuromuscular care, I recognize the profound anxiety that a genetic test for muscular dystrophy brings. This FHL1 analysis provides a clear molecular answer, but it must always be correlated with your clinical history, cardiac assessments, and family pedigree. Together, we will translate this information into a compassionate, personalized management plan that safeguards your heart and mobility.”
— Dr. Prabhakar Reddy, DHA License 61713011
⚠ Medication Warning: Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & ER Red Flags
- If you experience sudden chest pain, palpitations, fainting, or severe shortness of breath, seek emergency cardiac care immediately – these may signal dangerous arrhythmias or cardiomyopathy associated with EDMD.
- Blood draw is contraindicated in patients with severe uncontrolled coagulopathy or ongoing high-dose anticoagulant therapy without physician clearance.
- This test should be ordered only after a formal genetic counselling session and pedigree chart documentation, as required by the UAE CDS Law 2026 for minors and vulnerable groups.
Patient FAQ & Clinical Guidance
1. What is the FHL1 gene test and why is it performed?
The FHL1 gene NGS test identifies mutations causing Emery-Dreifuss muscular dystrophy type 6, enabling accurate diagnosis, family screening, and tailored management. This test analyzes the entire FHL1 gene for sequence variants and copy-number changes using high-throughput sequencing, offering a definitive explanation for muscle weakness, joint stiffness, and cardiac issues. Results guide neurologists, cardiologists, and genetic counselors in prognosis and preventive interventions.
ما هو تحليل جين FHL1 ولماذا يُجرى؟
يحدد اختبار التسلسل الجيني فائق الإنتاجية لجين FHL1 الطفرات المرتبطة بحثل إيمري-درايفوس العضلي النوع السادس، مما يتيح تشخيصًا دقيقًا وفحصًا عائليًا وخطة علاجية موجهة.
2. How accurate is this NGS test, and can it detect all mutations?
Our NGS achieves 99.9% diagnostic sensitivity for FHL1 coding regions, detecting point mutations, indels, and copy number variants. The analytical pipeline is validated against international standards and includes orthogonal confirmation of pathogenic findings. Rare deep intronic or epigenetic modifications may require additional targeted study, but comprehensive clinical correlation minimizes diagnostic gaps.
ما مدى دقة هذا الفحص، وهل يكشف جميع الطفرات؟
يتمتع اختبارنا بحساسية تشخيصية تصل إلى 99.9% للمناطق المشفّرة لجين FHL1، ويكتشف الطفرات النقطية والإدراج والحذف واختلافات عدد النسخ.
3. What is the sample collection process, and is home service available?
A trained phlebotomist performs a pain-free blood draw at your home, or you can provide DNA on an FTA card, ensuring convenience and sample stability. The sample is transported in an ISO-certified cold chain from 8 AM to 11 PM daily. Minimal preparation is required: hydration and a brief genetic counselling session beforehand can be arranged at the same visit.
كيف تتم عملية جمع العينة، وهل تتوفر خدمة السحب المنزلي؟
يقوم فني سحب مرخّص بأخذ عينة دم بطريقة غير مؤلمة في منزلك، أو يمكنك تقديم بقعة دم جافة على بطاقة FTA، مع سلسلة تبريد معتمدة طوال اليوم.
Facility License: 9834453 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)
Compliant with Federal Decree-Law No. 41 of 2024 (Art. 87), CDS Law 2026 (Minors), and UAE PDPL.
LOINC 51969-4 – FHL1 gene [Presence] in Blood or Tissue by Molecular Genetics Method.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians